EdgarLookup

Strategy Inc — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Strategy Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-830.3%
Profit Margin
Net income ÷ revenue
-6.2%
Return on Assets
Net income ÷ assets
0.24x
Debt-to-Equity
Total liabilities ÷ equity
-6.6%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $463.46M Feb 18, 2025
FY2024 Dec 31, 2023 $496.26M Feb 18, 2025
FY2024 Dec 31, 2022 $499.26M Feb 18, 2025
FY2023 Dec 31, 2021 $510.76M Feb 15, 2024
FY2022 Dec 31, 2020 $480.74M Feb 16, 2023
FY2021 Dec 31, 2019 $486.33M Feb 16, 2022
FY2020 Dec 31, 2018 $497.64M Feb 12, 2021
FY2017 Dec 31, 2017 $138.15M Feb 7, 2018
FY2017 Sep 30, 2017 $125.21M Feb 7, 2018
FY2017 Jun 30, 2017 $120.61M Feb 7, 2018

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $477.23M Feb 19, 2026
FY2025 Dec 31, 2024 $463.46M Feb 19, 2026
FY2025 Dec 31, 2023 $496.26M Feb 19, 2026
FY2024 Dec 31, 2022 $499.26M Feb 18, 2025
FY2023 Dec 31, 2021 $510.76M Feb 15, 2024
FY2020 Dec 31, 2020 $131.32M Feb 12, 2021
FY2020 Sep 30, 2020 $127.41M Feb 12, 2021
FY2020 Jun 30, 2020 $110.58M Feb 12, 2021
FY2020 Mar 31, 2020 $111.42M Feb 12, 2021
FY2020 Dec 31, 2019 $133.53M Feb 12, 2021

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $327.82M Feb 19, 2026
FY2025 Dec 31, 2024 $333.99M Feb 19, 2026
FY2025 Dec 31, 2023 $386.32M Feb 19, 2026
FY2024 Dec 31, 2022 $396.28M Feb 18, 2025
FY2023 Dec 31, 2021 $418.85M Feb 15, 2024
FY2020 Dec 31, 2020 $110.53M Feb 12, 2021
FY2020 Sep 30, 2020 $105.67M Feb 12, 2021
FY2020 Jun 30, 2020 $86.60M Feb 12, 2021
FY2020 Mar 31, 2020 $86.88M Feb 12, 2021
FY2020 Dec 31, 2019 $108.90M Feb 12, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($3.85B) Feb 19, 2026
FY2025 Dec 31, 2024 ($1.17B) Feb 19, 2026
FY2025 Dec 31, 2023 $429.12M Feb 19, 2026
FY2024 Dec 31, 2022 ($1.47B) Feb 18, 2025
FY2023 Dec 31, 2021 ($535.48M) Feb 15, 2024
FY2020 Dec 31, 2020 $2.66M Feb 12, 2021
FY2020 Sep 30, 2020 ($14.23M) Feb 12, 2021
FY2020 Jun 30, 2020 $3.39M Feb 12, 2021
FY2020 Mar 31, 2020 $657.0K Feb 12, 2021
FY2020 Dec 31, 2019 $12.17M Feb 12, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($5.44B) Feb 19, 2026
FY2025 Dec 31, 2024 ($1.85B) Feb 19, 2026
FY2025 Dec 31, 2023 ($115.05M) Feb 19, 2026
FY2024 Dec 31, 2022 ($1.28B) Feb 18, 2025
FY2023 Dec 31, 2021 ($784.53M) Feb 15, 2024
FY2022 Dec 31, 2020 ($13.63M) Feb 16, 2023
FY2021 Dec 31, 2019 ($1.00M) Feb 16, 2022
FY2020 Dec 31, 2018 $3.98M Feb 12, 2021
FY2019 Dec 31, 2017 $73.22M Feb 14, 2020
FY2018 Dec 31, 2016 $109.51M Feb 20, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $93.86M Feb 19, 2026
FY2025 Dec 31, 2024 $118.49M Feb 19, 2026
FY2025 Dec 31, 2023 $120.53M Feb 19, 2026
FY2024 Dec 31, 2022 $127.43M Feb 18, 2025
FY2023 Dec 31, 2021 $117.12M Feb 15, 2024
FY2022 Dec 31, 2020 $103.56M Feb 16, 2023
FY2021 Dec 31, 2019 $109.42M Feb 16, 2022
FY2020 Dec 31, 2018 $102.50M Feb 12, 2021
FY2019 Dec 31, 2017 $78.77M Feb 14, 2020
FY2018 Dec 31, 2016 $73.14M Feb 20, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($67.24M) Feb 19, 2026
FY2025 Dec 31, 2024 ($53.03M) Feb 19, 2026
FY2025 Dec 31, 2023 $12.71M Feb 19, 2026
FY2024 Dec 31, 2022 $3.21M Feb 18, 2025
FY2023 Dec 31, 2021 $93.83M Feb 15, 2024
FY2022 Dec 31, 2020 $53.62M Feb 16, 2023
FY2021 Dec 31, 2019 $60.87M Feb 16, 2022
FY2020 Dec 31, 2018 $10.63M Feb 12, 2021
FY2019 Dec 31, 2017 $78.32M Feb 14, 2020
FY2018 Dec 31, 2016 $110.59M Feb 20, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $8.21M Feb 19, 2026
FY2025 Dec 31, 2024 $2.98M Feb 19, 2026
FY2025 Dec 31, 2023 $2.94M Feb 19, 2026
FY2024 Dec 31, 2022 $2.49M Feb 18, 2025
FY2023 Dec 31, 2021 $2.71M Feb 15, 2024
FY2022 Dec 31, 2020 $3.65M Feb 16, 2023
FY2021 Dec 31, 2019 $10.18M Feb 16, 2022
FY2020 Dec 31, 2018 $6.85M Feb 12, 2021
FY2019 Dec 31, 2017 $3.98M Feb 14, 2020
FY2018 Dec 31, 2016 $2.34M Feb 20, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $61.64B Feb 19, 2026
FY2025 Dec 31, 2024 $25.84B Feb 19, 2026
FY2025 Dec 31, 2023 $4.76B Feb 19, 2026
FY2023 Dec 31, 2022 $2.41B Feb 15, 2024
FY2022 Dec 31, 2021 $3.56B Feb 16, 2023
FY2021 Dec 31, 2020 $1.47B Feb 16, 2022
FY2020 Dec 31, 2019 $916.57M Feb 12, 2021
FY2019 Dec 31, 2018 $855.77M Feb 14, 2020
FY2018 Dec 31, 2017 $933.22M Feb 20, 2019
FY2017 Dec 31, 2016 $768.32M Feb 7, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $10.60B Feb 19, 2026
FY2025 Dec 31, 2024 $7.61B Feb 19, 2026
FY2024 Dec 31, 2023 $2.60B Feb 18, 2025
FY2023 Dec 31, 2022 $2.79B Feb 15, 2024
FY2022 Dec 31, 2021 $2.58B Feb 16, 2023
FY2021 Dec 31, 2020 $912.57M Feb 16, 2022
FY2020 Dec 31, 2019 $408.01M Feb 12, 2021
FY2019 Dec 31, 2018 $326.04M Feb 14, 2020
FY2018 Dec 31, 2017 $327.49M Feb 20, 2019
FY2017 Dec 31, 2016 $216.14M Feb 7, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $44.12B Feb 19, 2026
FY2025 Dec 31, 2024 $18.23B Feb 19, 2026
FY2025 Dec 31, 2023 $2.16B Feb 19, 2026
FY2025 Dec 31, 2022 ($383.12M) Feb 19, 2026
FY2024 Dec 31, 2021 $978.96M Feb 18, 2025
FY2023 Dec 31, 2020 $446.19M Feb 15, 2024
FY2022 Dec 31, 2019 $508.56M Feb 16, 2023
FY2021 Dec 31, 2018 $529.73M Feb 16, 2022
FY2020 Dec 31, 2017 $605.73M Feb 12, 2021
FY2019 Dec 31, 2016 $566.32M Feb 14, 2020

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.32B Feb 19, 2026
FY2025 Jan 1, 2025 $10.58B Feb 19, 2026
FY2025 Dec 31, 2024 ($2.17B) Feb 19, 2026
FY2024 Dec 31, 2023 ($999.23M) Feb 18, 2025
FY2023 Dec 31, 2022 ($1.43B) Feb 15, 2024
FY2022 Dec 31, 2021 $41.44M Feb 16, 2023
FY2021 Dec 31, 2020 $575.97M Feb 16, 2022
FY2020 Dec 31, 2019 $583.49M Feb 12, 2021
FY2019 Dec 31, 2018 $549.13M Feb 14, 2020
FY2018 Dec 31, 2017 $526.63M Feb 20, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.30B Feb 19, 2026
FY2025 Dec 31, 2024 $38.12M Feb 19, 2026
FY2024 Dec 31, 2023 $46.82M Feb 18, 2025
FY2023 Dec 31, 2022 $43.84M Feb 15, 2024
FY2022 Dec 31, 2021 $63.36M Feb 16, 2023
FY2021 Dec 31, 2020 $59.68M Feb 16, 2022
FY2020 Dec 31, 2019 $456.73M Feb 12, 2021
FY2019 Dec 31, 2018 $109.92M Feb 14, 2020
FY2018 Dec 31, 2017 $420.24M Feb 20, 2019
FY2017 Dec 31, 2016 $401.98M Feb 7, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $8.19B Feb 19, 2026
FY2025 Dec 31, 2024 $7.19B Feb 19, 2026
FY2024 Dec 31, 2023 $2.18B Feb 18, 2025
FY2023 Dec 31, 2022 $2.38B Feb 15, 2024
FY2022 Dec 31, 2021 $2.16B Feb 16, 2023

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (15) Feb 19, 2026
FY2025 Dec 31, 2024 (6) Feb 19, 2026
FY2025 Dec 31, 2023 3 Feb 19, 2026
FY2024 Dec 31, 2022 (12) Feb 18, 2025
FY2023 Dec 31, 2021 (53) Feb 15, 2024
FY2020 Dec 31, 2020 0 Feb 12, 2021
FY2020 Sep 30, 2020 (1) Feb 12, 2021
FY2020 Jun 30, 2020 0 Feb 12, 2021
FY2020 Mar 31, 2020 0 Feb 12, 2021
FY2020 Dec 31, 2019 1 Feb 12, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (15) Feb 19, 2026
FY2025 Dec 31, 2024 (6) Feb 19, 2026
FY2025 Dec 31, 2023 2 Feb 19, 2026
FY2024 Dec 31, 2022 (12) Feb 18, 2025
FY2023 Dec 31, 2021 (53) Feb 15, 2024
FY2020 Dec 31, 2020 0 Feb 12, 2021
FY2020 Sep 30, 2020 (1) Feb 12, 2021
FY2020 Jun 30, 2020 0 Feb 12, 2021
FY2020 Mar 31, 2020 0 Feb 12, 2021
FY2020 Dec 31, 2019 1 Feb 12, 2021